Tech Company M&A Transactions
Syntimmune Acquisition
Syntimmune, operating out of Boston, was purchased by Alexion Pharmaceuticals. Deal value was $1.2 billion.
Transaction Overview
Company Name
Acquired By
Announced On
9/26/2018
Transaction Type
M&A
Amount
$1,200,000,000
M&A Terms
Under the terms of the agreement, Alexion will acquire Syntimmune for an upfront payment of $400 million, with the potential for additional milestone-dependent payments of up to $800 million, for a total value of up to $1.2 billion.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
116 Huntington Ave. 301
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Founded in 2013, Syntimmune is the world's leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Kress
Chief Financial Officer
John McBride
Chief Medical Officer
Mario Saltarelli
Vice President
Stephanie Haller
Vice President
Nicole Luosey
VP - Operations
Adam Hansard
VP - Regulatory Affairs
Donald Johns
VP - Regulatory Affairs
Leslie Stolz
Browse more venture capital transactions:
Prev: 9/26/2018: GigaIO venture capital transaction
Next: 9/26/2018: DNAtriX venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs